Oramed Pharmaceuticals (ORMP) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Oramed Pharmaceuticals (ORMP) has outperformed PepGen (PEPG) over the past year, gaining 75.7% versus a loss of 51.1%. Oramed Pharmaceuticals is the larger company by market cap ($174.7 million vs $164.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ORMP | PEPG |
|---|---|---|
| Share price | $4.20 | $2.38 |
| Market cap | $174.71M | $164.62M |
| 1-day change | -3.89% | -0.83% |
| YTD return | +47.37% | -63.44% |
| 1-year return | +75.73% | -51.13% |
| 5-year return | -80.96% | — |
| P/E ratio (TTM) | 1.02 | — |
| EPS (TTM) | $4.13 | $-1.01 |
| Dividend yield | 5.71% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.47 | $7.80 |
| 52-week low | $2.09 | $1.31 |
| Distance from 52-week high | -23.22% | -69.49% |
| Analyst consensus | none | none |
| Avg. price target upside | +66.67% | +328.15% |
| Average volume | 192.76K | 971.65K |
| Shares outstanding | 41.60M | 69.17M |
| Employees | — | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ORMP has outperformed PEPG by 126.9 percentage points over the past year.
- Oramed Pharmaceuticals offers a meaningfully higher dividend yield (5.71% vs 0.00%).
About Oramed Pharmaceuticals
ORMP stock →Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
Health Care · Biotechnology: Pharmaceutical Preparations
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
ORMP vs PEPG FAQ
Which is bigger, Oramed Pharmaceuticals or PepGen?
Oramed Pharmaceuticals (ORMP) is larger, with a market capitalization of $174.71M compared with $164.62M for PepGen (PEPG).
Which stock has performed better over the past year, ORMP or PEPG?
ORMP returned +75.73% over the past 12 months, compared with -51.13% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Oramed Pharmaceuticals or PepGen?
Oramed Pharmaceuticals pays a dividend yielding 5.71%, while PepGen does not currently pay a regular dividend.
Are Oramed Pharmaceuticals and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.